T. Rowe Price Investment Management, Inc. Immatics N.V. Transaction History
T. Rowe Price Investment Management, Inc.
- $151 Billion
- Q1 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Immatics N.V. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 14,677,003 shares of IMTX stock, worth $85.9 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
14,677,003
Previous 10,604,777
38.4%
Holding current value
$85.9 Million
Previous $75.4 Million
12.21%
% of portfolio
0.04%
Previous 0.05%
Shares
8 transactions
Others Institutions Holding IMTX
# of Institutions
81Shares Held
91.1MCall Options Held
201KPut Options Held
109K-
Perceptive Advisors LLC New York, NY9.38MShares$54.9 Million1.77% of portfolio
-
Suvretta Capital Management, LLC New York, NY9.14MShares$53.4 Million1.8% of portfolio
-
Wellington Management Group LLP Boston, MA8.58MShares$50.2 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY7.28MShares$42.6 Million0.39% of portfolio
-
Vestal Point Capital, LP New York, NY7.19MShares$42.1 Million2.32% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $446M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...